Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 12/20 | 0.75 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65179 | 0.90 | HDAC6 (0.69) | CHKAHRH3CA2NCF1PRMT6 | |
| SCHEMBL16356429 | 0.90 | HDAC6 (0.69) | CHKAHRH3CA2NCF1PRMT6 | |
| SCHEMBL16121572 | 0.89 | CHKA (0.75) | CHKAHRH3CA2NCF1PRMT6 | |
| Hydrochloric Acid SCHEMBL846616 | 0.88 | HDAC6 (0.68) | CHKAHRH3CA2NCF1PRMT6 | |
| Hydrochloric Acid SCHEMBL14763998 | 0.88 | HDAC6 (0.68) | CHKAHRH3CA2NCF1PRMT6 | |
| Hydrochloric Acid SCHEMBL3272318 | 0.88 | HDAC6 (0.68) | CHKAHRH3CA2NCF1PRMT6 | |
| Hydrochloric Acid SCHEMBL3664891 | 0.87 | HDAC6 (0.66) | CHKAHRH3CA2NCF1PRMT6 | |
| Hydrochloric Acid SCHEMBL1583152 | 0.87 | HDAC6 (0.66) | CHKAHRH3CA2NCF1PRMT6 | |
| SCHEMBL16121577 | 0.87 | CHKA (1.00) | CHKAHRH3CA2NCF1PRMT6 | |
| SCHEMBL16121966 | 0.86 | CHKA (0.75) | CHKAHRH3CA2NCF1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2014151761-A1 | NOVEL CHOLINE KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | CHKA, CHKB, CEPT1 | CHKA 1/4885HRH3 757/4885CA2 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.